HMP-2020-306-GLOB1
Phase I
OPEN TO ACCRUAL *
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
IIT-ATALLAH-MCW-XEN21
Phase I
OPEN TO ACCRUAL
MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
JNJ-75276617ALE1001
Phase I
OPEN TO ACCRUAL
A First in Human Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Participants with Acute Leukemia
KRONOS-KB-LANRA-1001
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT3-Mutated Relapsed or Refractory AML